Brief: Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis

AnaptysBio

09/05/2024 21:35

May 9 (Reuters) - AnaptysBio Inc  ANAB.O :
    * ANAPTYS ANNOUNCES POSITIVE TOP-LINE GEMINI-2 PHASE 3
CLINICAL
TRIAL RESULTS OF IMSIDOLIMAB (IL-36R) IN GENERALIZED PUSTULAR
PSORIASIS (GPP)
    * ANAPTYSBIO INC - SAFETY AND TOLERABILITY IN GEMINI-2
PATIENTS
WAS CONSISTENT WITH REPORTED PROFILE FROM GEMINI-1
    * ANAPTYSBIO INC - IMSIDOLIMAB WELL TOLERATED THROUGH END OF
STUDY
    * ANAPTYSBIO INC - WITH ALL PATIENTS HAVING PASSED 24 WEEKS
AND
FURTHEST PATIENT BEING TREATED THROUGH 92 WEEKS, COMPANY IS
CONCLUDING GEMINI-2 TRIAL
    * ANAPTYSBIO INC -  PLANS TO OUT-LICENSE IMSIDOLIMAB IN 2024

Source text for Eikon:  ID:nGNX436cWb 
Further company coverage:  ANAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))